Eisai already has a dementia drug on the U.S. market called Leqembi, co-developed with U.S. peer Biogen and the companies announced on Friday that they would start Leqembi sales in China, making that country the third where the treatment is available after the U.S. and Japan.
from Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/V4gplZ6
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment